Ir para o conteúdo principal

XORTX Therapeutics (NASDAQ: XRTX) — Perfil da empresa, notícias e dados financeiros

Logo de XORTX Therapeutics
XRTX XORTX Therapeutics
XORTX Therapeutics primary media
Perfil da empresa

XORTX Therapeutics

XORTX Therapeutics (CVE:XRTX), (NASDAQ:XRTX) focuses on developing innovative therapies aimed at treating kidney disease and conditions that lead to kidney damage. It is traded on the NASDAQ stock exchange under the ticker symbol XRTX. The company is dedicated to advancing its clinical programs to address unmet medical needs in the treatment of progressive kidney disease. XORTX's projects primarily involve the development of therapeutic solutions that target the underlying causes of kidney damage, including high uric acid levels and oxidative stress. Their objective is to improve the quality of life for patients suffering from these debilitating conditions through the advancement of their research and development efforts. By leveraging its expertise in kidney health, XORTX is committed to bringing novel treatments to market that can offer hope and improved outcomes for patients facing kidney-related health challenges.

Resumo

Public USParticipação acionária
2011Ano de fundação
3Funcionários
Calgary, CanadaSede
Carregando mapa...
Presença global

Operações

Todos os locais
Calgary, CA

Produtos e/ou serviços de XORTX Therapeutics

  • Development of novel therapeutics to treat progressive kidney disease in autosomal dominant polycystic kidney disease and other chronic kidney diseases.
  • Advancement of XRx-008 program for Alport syndrome, aiming to reduce hyperuricemia and improve kidney function.
  • Research on XRx-101, a formulation designed to mitigate acute kidney injury resulting from contrast media administration during medical procedures.
  • Exploration of treatments targeting uric acid pathways to address rare kidney diseases and potentially extend to more common renal ailments.
  • Investigation into metabolic syndrome interventions, focusing on therapeutics to manage and mitigate its impact on kidney health.
  • Pursuit of partnerships and collaborations to expand research and development efforts in kidney disease and related metabolic disorders.

equipe executiva do XORTX Therapeutics

  • Allen Warren DavidoffFounder, Co-CEO, President & Director
  • Michael Scott BumbyChief Financial Officer
  • Stephen HaworthChief Medical Officer
  • Stacy EvansChief Business Officer
  • Mika GrassoCo-CEO & Director
  • Nick RigopulosDirector of Communications
  • David SansDirector of Corporate Development
  • David MacDonaldConsultant of Clinical Operations
  • Charlotte MayCorporate Secretary

Últimas notícias sobre a XORTX Therapeutics

Principais indicadores financeiros

Resultados divulgados pela XORTX Therapeutics, em USD.

Cap. de mercado
2 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-2.6
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da XORTX Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-3,3 mi-2,7 mi
0-3,9 mi-3,2 mi
0-6 mi-2,2 mi
0-12,4 mi-10,5 mi